Design of PD-L1 Inhibitors for Lung Cancer

Bioinformation
doi 10.6026/97320630015139
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Biomedical Informatics

Related search

P2.01-82 Neutrophil-To-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pharmacoeconomic Evaluation of PD-L1 Receptor Inhibitors for the Second Line Treatment of Metastatic Non-Small Cell Lung Cancer

Medical Technologies. Assessment and Choice
2018English

Immunotherapies Based on PD-1/PD-L1 Pathway Inhibitors in Ovarian Cancer Treatment

Clinical and Experimental Immunology
AllergyImmunology
2019English

Aspirin‐targeted PD‐L1 in Lung Cancer Growth Inhibition

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

PD-L1 Gene Expression in Japanese Lung Cancer Patients

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2012English

Real-World Evidenceand Clinical Observations of the Treatment of Advanced Non-Small Cell Lung Cancer With PD-1/PD-L1 Inhibitors

Scientific Reports
Multidisciplinary
2019English

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature

Cancer
Cancer ResearchOncology
2017English

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy